SG Americas Securities LLC Sells 7,991 Shares of Balchem Co. (NASDAQ:BCPC)

SG Americas Securities LLC reduced its position in Balchem Co. (NASDAQ:BCPC - Free Report) by 71.2% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 3,236 shares of the basic materials company's stock after selling 7,991 shares during the period. SG Americas Securities LLC's holdings in Balchem were worth $570,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bessemer Group Inc. boosted its holdings in Balchem by 568.9% in the 1st quarter. Bessemer Group Inc. now owns 301 shares of the basic materials company's stock valued at $47,000 after purchasing an additional 256 shares during the period. GAMMA Investing LLC raised its holdings in shares of Balchem by 18.0% in the 1st quarter. GAMMA Investing LLC now owns 473 shares of the basic materials company's stock valued at $73,000 after acquiring an additional 72 shares in the last quarter. TD Asset Management Inc bought a new stake in shares of Balchem during the 2nd quarter valued at about $200,000. Heritage Family Offices LLP purchased a new position in shares of Balchem during the second quarter worth about $206,000. Finally, Sage Rhino Capital LLC purchased a new stake in Balchem in the second quarter valued at approximately $207,000. Institutional investors own 87.91% of the company's stock.

Insider Buying and Selling at Balchem

In other Balchem news, SVP Gunsteren Job Leonard Van sold 7,750 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $180.05, for a total value of $1,395,387.50. Following the completion of the sale, the senior vice president now owns 8,540 shares in the company, valued at approximately $1,537,627. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.25% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on BCPC. StockNews.com lowered shares of Balchem from a "buy" rating to a "hold" rating in a report on Monday, July 29th. HC Wainwright raised their price target on Balchem from $170.00 to $185.00 and gave the company a "buy" rating in a research report on Wednesday, July 31st.

Balchem Price Performance

BCPC traded down $0.36 during midday trading on Tuesday, hitting $172.01. The stock had a trading volume of 83,478 shares, compared to its average volume of 106,879. Balchem Co. has a 1 year low of $110.74 and a 1 year high of $186.03. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.79 and a current ratio of 2.83. The business has a fifty day moving average of $170.83 and a 200 day moving average of $161.26. The company has a market cap of $5.58 billion, a P/E ratio of 48.59, a price-to-earnings-growth ratio of 5.43 and a beta of 0.65.

Balchem (NASDAQ:BCPC - Get Free Report) last announced its quarterly earnings data on Friday, July 26th. The basic materials company reported $0.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.95 by $0.03. Balchem had a net margin of 12.52% and a return on equity of 10.94%. The company had revenue of $234.08 million during the quarter, compared to analysts' expectations of $241.26 million. As a group, equities analysts forecast that Balchem Co. will post 3.96 earnings per share for the current fiscal year.

Balchem Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.